Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
Ludwig Heesen(Uppsala University Hospital), Uğur Şahin(Johannes Gutenberg University Mainz), Sebastian Kreiter(Johannes Gutenberg University Mainz), Tobias Sjöblom(Uppsala University), Klaus Kühlcke(Institute of Bioinformatics and Systems Biology), Stefanie Bolte(BioNTech (Germany)), Katrin Frenzel(Uppsala University Hospital), Marcus Schmidt(Johannes Gutenberg University Mainz), Evelyna Derhovanessian(University of Tübingen), Henrik Lindman(Uppsala University), Laurence Zitvogel(Institut Gustave Roussy), Kris Thielemans(Erasmus Hospital), Valesca Bukur(Uppsala University Hospital), Mustafa Diken, Steve Pascolo(University of Zurich), Andreas Schneeweiß(German Cancer Research Center), Özlem Türeci(Johannes Gutenberg University Mainz), Martin Löwer, Andreas N. Kuhn(Uppsala University Hospital)
Cited by 2
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
|Science|2006|3.2k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k